vs
Side-by-side financial comparison of ECARX Holdings Inc. (ECX) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $323.3M, roughly 1.0× ECARX Holdings Inc.). HAEMONETICS CORP runs the higher net margin — 13.2% vs -21.4%, a 34.6% gap on every dollar of revenue. On growth, ECARX Holdings Inc. posted the faster year-over-year revenue change (6.5% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-86.5M).
ECARX Holdings Inc. is a global mobility technology provider specializing in integrated smart vehicle solutions, including in-vehicle infotainment systems, advanced driver assistance technologies, and connected car cloud services. It primarily partners with automotive manufacturers across the world, with a strong operational presence in the Chinese and European markets.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
ECX vs HAE — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $323.3M | $339.0M |
| Net Profit | $-69.1M | $44.7M |
| Gross Margin | 15.5% | 59.7% |
| Operating Margin | -20.2% | 19.9% |
| Net Margin | -21.4% | 13.2% |
| Revenue YoY | 6.5% | -2.7% |
| Net Profit YoY | 12.8% | 19.3% |
| EPS (diluted) | $-0.20 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $339.0M | ||
| Q3 25 | — | $327.3M | ||
| Q2 25 | $323.3M | $321.4M | ||
| Q1 25 | — | $330.6M | ||
| Q4 24 | — | $348.5M | ||
| Q3 24 | — | $345.5M | ||
| Q2 24 | $303.5M | $336.2M | ||
| Q4 23 | — | $336.3M |
| Q4 25 | — | $44.7M | ||
| Q3 25 | — | $38.7M | ||
| Q2 25 | $-69.1M | $34.0M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $37.5M | ||
| Q3 24 | — | $33.8M | ||
| Q2 24 | $-79.2M | $38.4M | ||
| Q4 23 | — | $31.2M |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | 15.5% | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | 22.6% | 52.0% | ||
| Q4 23 | — | 52.9% |
| Q4 25 | — | 19.9% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | -20.2% | 16.8% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 15.0% | ||
| Q2 24 | -22.2% | 11.8% | ||
| Q4 23 | — | 13.7% |
| Q4 25 | — | 13.2% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | -21.4% | 10.6% | ||
| Q1 25 | — | 17.5% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | -26.1% | 11.4% | ||
| Q4 23 | — | 9.3% |
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | $-0.20 | $0.70 | ||
| Q1 25 | — | $1.17 | ||
| Q4 24 | — | $0.74 | ||
| Q3 24 | — | $0.66 | ||
| Q2 24 | $-0.23 | $0.74 | ||
| Q4 23 | — | $0.61 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.2M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $-293.7M | $911.5M |
| Total Assets | $494.9M | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | $86.2M | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | — | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | $108.4M | $344.4M | ||
| Q4 23 | — | $194.0M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | — | $911.5M | ||
| Q3 25 | — | $849.2M | ||
| Q2 25 | $-293.7M | $882.3M | ||
| Q1 25 | — | $820.8M | ||
| Q4 24 | — | $906.9M | ||
| Q3 24 | — | $878.9M | ||
| Q2 24 | $-198.5M | $905.4M | ||
| Q4 23 | — | $943.3M |
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | $494.9M | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | $555.0M | $2.5B | ||
| Q4 23 | — | $2.2B |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.0M | $93.6M |
| Free Cash FlowOCF − Capex | $-86.5M | $87.2M |
| FCF MarginFCF / Revenue | -26.7% | 25.7% |
| Capex IntensityCapex / Revenue | 1.4% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $93.6M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | $-82.0M | $17.4M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | — | $43.8M | ||
| Q3 24 | — | $48.8M | ||
| Q2 24 | $-57.1M | $-27.4M | ||
| Q4 23 | — | $-540.0K |
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | $-86.5M | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | $-64.9M | $-33.1M | ||
| Q4 23 | — | $-15.2M |
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | -26.7% | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | -21.4% | -9.8% | ||
| Q4 23 | — | -4.5% |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | 1.4% | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | 2.6% | 1.7% | ||
| Q4 23 | — | 4.4% |
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q4 23 | — | -0.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECX
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
